-- Robert I Blum, Director, President & CEO, on April 29, 2026, sold 7,500 shares in Cytokinetics (CYTK) for $447,150. Following the Form 4 filing with the SEC, Blum has control over a total of 411,996 common shares of the company, with 407,830 shares held directly and 4,166 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1061983/000106198326000044/xslF345X05/form4.xml